Table 1 Demographic and clinical features of patients
Number of patients (%) | |
|---|---|
Total | 45 |
Age, mean (Min–Max) (year) | 61,60 ± 9,946 (42–82) |
PFS, median (month) | 13 |
Average follow-up time, median (month) | 19 |
ECOG | |
0 | 35 (77.8) |
1 | 10 (22.2) |
Stage at the time of diagnosis | |
Stage IIIB | 1 (2.2) |
Stage IIIC | 31 (68.9) |
Stage IVA | 1 (2.2) |
Stage IVB | 12 (26.7) |
Grade | |
High grade | 41 (91.1) |
Unknown | 4 (8.9) |
Chemotherapy response score | |
CRS 1 | 8 (17.8) |
CRS 2 | 28 (62.2) |
CRS 3 | 9 (20.0) |
Chemotherapy regimen | |
Carboplatin + paclitaxel | 41 (91.1) |
Others | 4 (8.9) |
Intratumoral CD8 + TILs | |
Low expression | 25 (55.6) |
High expression | 20 (44.4) |
Stromal CD8 + TILs | |
Low expression | 10 (22.2) |
High expression | 35 (77.8) |
Intratumoral PD-L1 | |
Low expression (< 1%) | 17 (37,8) |
High expression (≥ 1%) | 28 (52.2) |
Stromal PD-L1 | |
Low expression (< 1%) | 12 (26,7) |
High expression (≥ 1%) | 33 (73,3) |
Recurrence | |
Yes | 21 (46.7) |
No | 24 (53.3) |
Latest Status | |
Live | 39 (86.6) |
Dead | 6 (13.3) |